Orbsen Therapeutics

Orbsen Therapeutics is a private, clinical-stage biotech developing immunomodulatory cell therapies for serious conditions with high unmet need, including Diabetic Kidney Disease (DKD) and Acute Respiratory Distress Syndrome (ARDS). Its lead candidate, ORBCEL™, is a purified MSC therapy designed to target specific immune pathways driving inflammation and fibrosis. The company has advanced ORBCEL™ into Phase 2 clinical trials, supported by significant non-dilutive EU grant funding, and is actively fundraising to progress its pipeline. Orbsen operates from a new headquarters in Galway, positioning itself at the forefront of next-generation cell therapy.

ORBCEL™ platform: proprietary process for purifying allogeneic, bone marrow-derived mesenchymal stromal cells (MSCs) to create a targeted, off-the-shelf immunotherapy designed to modulate specific immune pathways driving inflammation and fibrosis.

Orbsen competes in the crowded MSC therapy space, but differentiates with its purified ORBCEL™ product. It faces competition from other cell therapy biotechs and large pharma companies developing small molecules and biologics for kidney disease, fibrosis, and inflammation. Success hinges on demonstrating superior efficacy through its targeted mechanism.